Your browser doesn't support javascript.
loading
Germline Missense Variants in CDC20 Result in Aberrant Mitotic Progression and Familial Cancer.
Chen, Owen J; Castellsagué, Ester; Moustafa-Kamal, Mohamed; Nadaf, Javad; Rivera, Barbara; Fahiminiya, Somayyeh; Wang, Yilin; Gamache, Isabelle; Pacifico, Caterina; Jiang, Lai; Carrot-Zhang, Jian; Witkowski, Leora; Berghuis, Albert M; Schönberger, Stefan; Schneider, Dominik; Hillmer, Morten; Bens, Susanne; Siebert, Reiner; Stewart, Colin J R; Zhang, Ziguo; Chao, William C H; Greenwood, Celia M T; Barford, David; Tischkowitz, Marc; Majewski, Jacek; Foulkes, William D; Teodoro, Jose G.
Affiliation
  • Chen OJ; Goodman Cancer Institute, McGill University, Montréal, Québec, Canada.
  • Castellsagué E; Department of Biochemistry, McGill University, Montréal, Québec, Canada.
  • Moustafa-Kamal M; Department of Human Genetics, McGill University, Montréal, Québec, Canada.
  • Nadaf J; Division of Medical Genetics and Cancer Axis, Lady Davis Institute, Segal Cancer Centre, Jewish General Hospital, Montréal, Québec, Canada.
  • Rivera B; Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Fahiminiya S; Goodman Cancer Institute, McGill University, Montréal, Québec, Canada.
  • Wang Y; Department of Biochemistry, McGill University, Montréal, Québec, Canada.
  • Gamache I; McGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.
  • Pacifico C; Cancer Axis, Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.
  • Jiang L; Hereditary Cancer Programme, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Carrot-Zhang J; Gerald Bronfman Department of Oncology, McGill University, Montréal, Québec, Canada.
  • Witkowski L; Department of Human Genetics, McGill University, Montréal, Québec, Canada.
  • Berghuis AM; Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada.
  • Schönberger S; Goodman Cancer Institute, McGill University, Montréal, Québec, Canada.
  • Schneider D; Department of Biochemistry, McGill University, Montréal, Québec, Canada.
  • Hillmer M; Goodman Cancer Institute, McGill University, Montréal, Québec, Canada.
  • Bens S; Goodman Cancer Institute, McGill University, Montréal, Québec, Canada.
  • Siebert R; Department of Biology, McGill University, Montréal, Québec, Canada.
  • Stewart CJR; Cancer Axis, Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.
  • Zhang Z; Department of Epidemiology, Biostatistics & Occupational Health, McGill University, Montréal, Québec, Canada.
  • Chao WCH; Department of Human Genetics, McGill University, Montréal, Québec, Canada.
  • Greenwood CMT; Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada.
  • Barford D; Department of Human Genetics, McGill University, Montréal, Québec, Canada.
  • Tischkowitz M; Division of Medical Genetics and Cancer Axis, Lady Davis Institute, Segal Cancer Centre, Jewish General Hospital, Montréal, Québec, Canada.
  • Majewski J; Department of Biochemistry, McGill University, Montréal, Québec, Canada.
  • Foulkes WD; Centre de Recherche en Biologie Structurale, McGill University, Montréal, Québec, Canada.
  • Teodoro JG; Department of Microbiology and Immunology, Montréal, Québec, Canada.
Cancer Res ; 82(19): 3499-3515, 2022 Oct 04.
Article in En | MEDLINE | ID: mdl-35913887
ABSTRACT
CDC20 is a coactivator of the anaphase promoting complex/cyclosome (APC/C) and is essential for mitotic progression. APC/CCDC20 is inhibited by the spindle assembly checkpoint (SAC), which prevents premature separation of sister chromatids and aneuploidy in daughter cells. Although overexpression of CDC20 is common in many cancers, oncogenic mutations have never been identified in humans. Using whole-exome sequencing, we identified heterozygous missense CDC20 variants (L151R and N331K) that segregate with ovarian germ cell tumors in two families. Functional characterization showed these mutants retain APC/C activation activity but have impaired binding to BUBR1, a component of the SAC. Expression of L151R and N331K variants promoted mitotic slippage in HeLa cells and primary skin fibroblasts derived from carriers. Generation of mice carrying the N331K variant using CRISPR-Cas9 showed that, although homozygous N331K mice were nonviable, heterozygotes displayed accelerated oncogenicity of Myc-driven cancers. These findings highlight an unappreciated role for CDC20 variants as tumor-promoting genes.

SIGNIFICANCE:

Two germline CDC20 missense variants that segregate with cancer in two families compromise the spindle assembly checkpoint and lead to aberrant mitotic progression, which could predispose cells to transformation. See related commentary by Villarroya-Beltri and Malumbres, p. 3432.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Spindle Apparatus / Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Cancer Res Year: 2022 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Spindle Apparatus / Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Cancer Res Year: 2022 Document type: Article Affiliation country: